Biotech Values

[DewDiligence]

ABIO—>ORKA effective Monday following 1:12 reverse split, pursuant to previously announced reverse-merger:

https://www.globenewswire.com/news-release/2024/08/29/2938141/0/en/ARCA-biopharma-Announces-Completion-of-Merger-with-Oruka-Therapeutics-and-Implementation-of-Reverse-Stock-Split.html

The combined company will operate under the name, Oruka Therapeutics, Inc., and its shares will begin trading on The Nasdaq Global Market on a post-reverse split, post-merger basis under the ticker symbol “ORKA” effective with the open of business on Tuesday, September 3, 2024.

…Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.